TKP Masthead

Hype Cycle Alert: Play This Biotech Breakout For Big Gains

Welcome to your Hype Cycle Insider report!

Remember, these monthly bonus reports exclusively for Technology Profits Confidential PRO readers pull back the curtain on a stock that's ramping up the innovation curve so that you can act before mainstream investors are paying attention.

Driven by a spate of high-profile buyouts since spring, biotech has been hot! The S&P Biotech ETF, which tracks the biotech sector, has risen 20% since early April. 

Biotech buyouts are driven by Big Pharma greed. Commercial-stage pharmaceutical companies own perishable assets in the form of patent drugs, drugs which can suddenly be worth much less when they come off patent and generic competition hits.

So, besides internal research and development, pharmaceutical companies with enough cash often go out and buy promising junior players—biotechs--with assets either looking like they will succeed in the market, or are already doing so. 

Axsome Therapeutics (NASDAQ: AXSM) could be one of those companies. The $3.69 billion company has been trading in a range all year, but earlier this month started to break out, suggesting higher share prices are in its future.

chart

Investors have good reason to get excited about Axsome. The company has been developing a new drug to treat major depressive disorder. The drug, called AXS-05, targets receptors of the central nervous system. 

AXS-05 is a proprietary formulation consisting of two components. One is dextromethorphan (DM), a common component of cough suppressants. The second is bupropion, an existing antidepressant. The combination drug is formulated in such a way as to inhibit the metabolism of DM, so it can stay in the brain longer, where it can modulate an array of cell receptors and neurotransmitters. Bupropion itself is used to treat depression, where it affects neurotransmitters like dopamine as well as norepinephrine. Combining the two is synergistic, with bupropion increasing the bioavailability of DM.

In Phase 3 trials AXS-05 showed a marked diminution in depressive symptoms, with 53% scoring improvements compared to only 33% on placebo. On another measure, 47% of patients reported feeling much, or very much improved when taking the drug.

Success in this Phase 3 trial sets Axsome up for a new drug application at the FDA, something it plans to do in the fourth quarter of this year. Since AXS-05 has already received Breakthrough Therapy Designation from the FDA, I believe it is highly likely Axsome will see this drug receive priority review, too. Priority means the review and decision on AXS-05’s application would only take 6 months instead of 10 months.

The FDA approved Axsome’s depression treatment last October, and the company is steadily growing sales numbers. But AXS-05 is also in Phase 3 clinical development for Alzheimer’s Disease agitation, as well as a smoking cessation aid. Add to that an additional three drugs in the pipeline. One drug is AXS-07, which the company expects to file for regulatory approval next quarter for migraines. Another, AXS-12, is expected to generate results from a Phase 3 trial in narcolepsy later this month.

But the real shocker is what Axsome believes its drugs will generate in terms of sales. Axsome expects that once approved, its stable of new drugs could pull in up to $11.5 billion, implying a huge upside from its current price. Even analysts' forecasts, which don’t include the sales potential for all of Axsome’s drugs, range up to $4.5 billion per year—still a huge opportunity at current prices. 

That makes this month’s breakout in AXSM shares a great buy opportunity.

Consider buying shares of Axsome Therapeutics (NASDAQ: AXSM)

Important Note: As a reminder, Hype Cycle Insider picks are an exclusive bonus benefit for Technology Profits Confidential PRO readers like you but they aren’t official Tech Profits Confidential recommendations. That means we won't track this stock in our model portfolio. If you choose to buy, plan your entry and exit carefully. Never invest money you can't afford to lose.

Want More Technology Profits Confidential Pro?

Do you like this content? Would you like to know more? Because we have this and much more to share with you. Get started today!

3 Phony Threats Not Worth Your Worry Time

Worrying about a crisis-filled world is understandable. But many are devoting time and effort to matters that aren’t even real crises. Jim provides three phony threats to take off your worry list and feel better about crises that don’t exist.

Read More

aln-update-06-13-25-img-post

Iran War Alert: Buy Cyber

Israel’s attack on Iran underscores an important pattern that’s developing in the market - the growing need for cybersecurity in the face of increasingly powerful AI. Here’s how to play it…

Read More

Stablecoins: What Could Go Wrong?

Meme coins and stablecoins are dominating the crypto world recently. Are they good investments or openings for fraud? In today’s state of the market briefing, Jim details how average investors are impacted and why no regulation could spell disaster for financial markets.

Read More

shutterstock 2611820997 (1)

Weekly Update: A Stacked Strategy

Today, let’s talk about an important system behind our investment strategy.

Read More

ALN-Alert-05-21-25(1)

Elon’s “King Kong” Unleashed On The Middle East

When Musk joined President Trump in Saudi Arabia last week, he supercharged an already-brewing AI revolution. And one of our portfolio companies has been actively developing Saudi talent for this AI future. Here’s everything you need to know…

Read More

pmg-update-05-14-25-post-img

The Next AI Rush Isn’t Digital

For the past two years, AI's been all about language. But now there’s a new frontier. And Elon Musk is prepared for it. Here’s why it matters…

Read More

shutterstock 1924036217

The China Con

This week’s mailbag included questions on China as a superpower, threats to the global financial system, and the best way to invest in gold.

Read More

America’s AI-Powered Nervous System

A fundamental restructuring of American manufacturing is now underway. Today, I want to show you the companies that are emerging as the backbone of this transformation.

Read More

shutterstock 1927192892

COMING SOON! My American Wealth Summit

This week, learn more about how to attend my latest wealth summit. Also, I answer more questions on a U.S. sovereign wealth fund as well as the best way to play the market during recent volatility.

Read More

The Great Gain: While Markets Crumble...

Wall Street just gave investors whiplash. But amidst the chaos, one asset class is showing remarkable resilience... Cryptocurrencies. This stability during market madness isn't happening by accident. Something bigger is brewing beneath the surface of the crypto markets.

Read More